George C. Prendergast

George C. Prendergast
George C. Prendergast
Born	Philadelphia, Pennsylvania
Alma mater	Princeton University (PhD); Yale University (MS); University of Pennsylvania (BA)
Awards	1995 Pew Scholar in the Biomedical Sciences
	Scientific career
Fields	Oncology, Molecular biology, Oncoimmunology
Institutions	Lankenau Institute for Medical Research; DuPont Pharmaceuticals Company; The Wistar Institute; Merck Research Laboratories; Howard Hughes Medical Institute

George C. Prendergast (born 1961) is an American cancer research scientist, who is President and CEO of Lankenau Institute for Medical Research.^[1] Co-leader of the Program in Cancer Cell Biology & Signaling at Kimmel Cancer Center, Thomas Jefferson University;^[2] and former Editor-in-Chief of Cancer Research, the most highly cited journal in the field, a journal of the American Association for Cancer Research

Muller, AJ; Duhadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC (2005). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312. doi:10.1038/nm1196. PMID 15711557.
Prendergast, G; Ziff, E (1991). "Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region". Science. 251 (4990): 186. Bibcode:1991Sci...251..186P. doi:10.1126/science.1987636. PMID 1987636.
Prendergast, GC; Lawe, D; Ziff, EB (1991). "Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation". Cell. 65 (3): 395. doi:10.1016/0092-8674(91)90457-A. PMID 1840505.

References